AbbVie Inc. $ABBV Shares Sold by Courier Capital LLC

Courier Capital LLC cut its stake in AbbVie Inc. (NYSE:ABBV) by 82.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,756 shares of the company’s stock after selling 13,119 shares during the period. Courier Capital LLC’s holdings in AbbVie were worth $721,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. State Street Corp raised its position in shares of AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after buying an additional 1,379,232 shares during the last quarter. Corient Private Wealth LP acquired a new stake in AbbVie during the second quarter worth about $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in AbbVie by 0.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after buying an additional 106,091 shares in the last quarter. Legal & General Group Plc bought a new position in AbbVie during the second quarter valued at about $2,905,952,000. Finally, Deutsche Bank AG increased its stake in AbbVie by 13.0% during the second quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock valued at $2,710,905,000 after acquiring an additional 1,241,587 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have commented on the company. Wells Fargo & Company raised their price objective on AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a research report on Monday, August 17th. HSBC boosted their price objective on AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Royal Bank Of Canada restated an “outperform” rating and issued a $280.00 target price on shares of AbbVie in a research note on Tuesday. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Finally, UBS Group raised their target price on AbbVie from $260.00 to $275.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $277.18.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Potential third-quarter revenue beat: RBC expects AbbVie to exceed top-line estimates, driven by continued momentum in Skyrizi, Rinvoq and Vraylar. The outlook reinforces the company’s ability to offset ongoing Humira erosion ahead of its quarterly results. AbbVie Poised for Q3 Top-Line Beat Driven by Rinvoq, Skyrizi, and Vraylar Therapies, RBC Says
• Positive Sentiment: Encouraging Skyrizi data: New Phase 3 AFFIRM results showed favorable clinical and endoscopic outcomes for subcutaneous Skyrizi in patients with moderately to severely active Crohn’s disease. The data could support broader use of the therapy and strengthen AbbVie’s post-Humira growth strategy. AbbVie Presents New Phase 3 AFFIRM Data
• Positive Sentiment: Pipeline and franchise expansion: Recent Skyrizi and Rinvoq data presented at ACG 2026, along with new oncology designations and early metabolic-program results, are broadening the investment case beyond immunology. Analysts also point to a recently completed acquisition and a fresh FDA approval as potential future growth drivers. AbbVie Highlights Long-Term SKYRIZI, RINVOQ Data Findings
• Positive Sentiment: Analyst support: Royal Bank of Canada reaffirmed its “Outperform” rating and set a $280 price target, while broader commentary describes AbbVie’s pipeline as potentially undervalued. The stock also remains attractive to income-focused investors because of its dividend profile. RBC Reaffirms AbbVie Outperform Rating
• Neutral Sentiment: Investor debate continues: Comparisons with Eli Lilly highlight AbbVie’s steadier diversification through Skyrizi and Rinvoq versus Lilly’s faster cardiometabolic growth, leaving investors divided over relative upside.
• Negative Sentiment: Key risks remain: Humira sales continue to decline, immunology competition is increasing, and AbbVie’s elevated valuation leaves less room for disappointing results or weaker guidance.

Insider Buying and Selling

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

AbbVie Trading Down 2.2%

NYSE:ABBV traded down $6.30 during mid-day trading on Tuesday, hitting $274.82. The company’s stock had a trading volume of 6,408,343 shares, compared to its average volume of 6,414,627. The company has a market capitalization of $485.55 billion, a price-to-earnings ratio of 77.63, a P/E/G ratio of 1.26 and a beta of 0.24. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $283.43. The stock has a fifty day moving average of $259.79 and a 200-day moving average of $237.39.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the previous year, the business earned $2.97 earnings per share. The company’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 13.94 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.